Key Insights

Highlights

Success Rate

87% trial completion (above average)

Published Results

24 trials with published results (44%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

11.1%

6 terminated out of 54 trials

Success Rate

86.7%

+0.2% vs benchmark

Late-Stage Pipeline

17%

9 trials in Phase 3/4

Results Transparency

62%

24 of 39 completed with results

Key Signals

24 with results87% success

Data Visualizations

Phase Distribution

52Total
Not Applicable (6)
Early P 1 (3)
P 1 (16)
P 2 (18)
P 3 (4)
P 4 (5)

Trial Status

Completed39
Terminated6
Unknown5
Withdrawn3
Recruiting1

Trial Success Rate

86.7%

Benchmark: 86.5%

Based on 39 completed trials

Clinical Trials (54)

Showing 20 of 20 trials
NCT04907357Not ApplicableCompleted

rTMS for Stimulant Use Disorders

NCT00882037CompletedPrimary

Risk and Protective Factors for Rural Methamphetamine Dependence

NCT00332605Phase 2CompletedPrimary

N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence

NCT01062451Phase 1CompletedPrimary

An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence

NCT01077024Phase 3Completed

Smoking-Cessation and Stimulant Treatment (S-CAST)

NCT00653263CompletedPrimary

Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study

NCT00730522Phase 2TerminatedPrimary

Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence

NCT01685463Not ApplicableCompletedPrimary

Transcranial Magnetic Stimulation Used to Both Measure Cortical Excitability and Explore Methamphetamine Cue Craving

NCT00469508Phase 2CompletedPrimary

Modafinil vs Placebo for the Treatment of Methamphetamine Dependence

NCT02058966Early Phase 1CompletedPrimary

Pilot Study of Entacapone for Methamphetamine Abuse

NCT00751023Phase 4CompletedPrimary

Effects of Modafinil in Methamphetamine Dependence

NCT01860807Phase 2CompletedPrimary

Trial of Ibudilast for Methamphetamine Dependence

NCT01967381Early Phase 1Completed

Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse

NCT01071356Phase 2CompletedPrimary

Intensive Motivational Interviewing for Methamphetamine Dependence

NCT01843205Phase 1CompletedPrimary

Buspirone as a Candidate Medication for Methamphetamine Abuse

NCT01365819Phase 2CompletedPrimary

Varenicline for Methamphetamine Dependence

NCT00859573Phase 2TerminatedPrimary

Modafinil for Methamphetamine Dependence

NCT02034201Phase 1CompletedPrimary

Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence

NCT01825928Not ApplicableCompletedPrimary

An Study of Paliperidone Extended-Release Tablets in the Treatment of Methamphetamine Dependence

NCT01019707Phase 1Terminated

Safety Assessment of Atomoxetine With MA IV Administration

Scroll to load more

Research Network

Activity Timeline